ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Kunz on Sequencing Agents for Pancreatic NETs

Pamela L. Kunz, MD
Published: Friday, Oct 10, 2014

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses sequencing agents for the treatment of pancreatic NETs.

The appropriate sequencing of agents in this area is an important unanswered question. Currently, there are no head-to-head trials looking at what agents should be given in the first line.

Today, academic and community oncologists must weigh patient characteristics (pace of disease growth, tumor bulk, grade, and patient preference) and drug characteristics (method of administration and side effects) to make their decision on a first line agent.

<<< View more from NANETS

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses sequencing agents for the treatment of pancreatic NETs.

The appropriate sequencing of agents in this area is an important unanswered question. Currently, there are no head-to-head trials looking at what agents should be given in the first line.

Today, academic and community oncologists must weigh patient characteristics (pace of disease growth, tumor bulk, grade, and patient preference) and drug characteristics (method of administration and side effects) to make their decision on a first line agent.

<<< View more from NANETS


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Medical Crossfire®: Navigating Treatment Decisions in Pancreatic Cancer: Key QuestionsJun 29, 20191.5
Publication Bottom Border
Border Publication
x